Eli Lilly’s Q2 2025 Revenue Surges 38% Driven by Mounjaro and Zepbound, Raises Full-Year Guidance Despite Stock Dip
Eli Lilly reported a remarkable 38% revenue increase in Q2 2025, reaching $15.56 billion, driven by strong demand for its flagship weight management and diabetes drugs, Mounjaro and Zepbound. The company raised its full-year revenue guidance to $60-62 billion and boosted earnings per share projections, reflecting confidence in continued growth. Expansion in international markets and strategic acquisitions further strengthen Eli Lilly’s innovation pipeline, particularly in obesity and cardiometabolic health. Despite the earnings beat, the stock experienced a dip, highlighting complex market dynamics amid robust business performance. This positions Eli Lilly as a leading player in the GLP-1 market and underscores its commitment to advancing treatments in obesity and cardiovascular disease.


